BRAF and thyroid cancer: To establish the sensitivity of thyroid cancer cell lines to BRAFi, growth rate (Fig. 1a), cell viability (Fig. 1b) and cell cycle distribution (Fig. 1c) were evaluated in response to PLX4032 in TC cell lines harboring the BRAF V600E mutation (i.e., BHT101, FRO and BCPAP cells) or BRAF-wild type WRO cells.